Merck Patent Gmbh

Merck Patent Gesellschaft MIT Beschrankter Haftung

Merck Patent Gesellschaft MIT Beschraenkter Haftung

Christiane Amendt

Frank Zenke

Hans-Peter Buchstaller

Dirk Finsinger

Alfred Jonczyk

Guenter Hoelzemann

Dieter Dorsch

Kai Schiemann

Matthias Wiesner

Matthias Grell

Ulrich Emde

Oliver Schadt

Manfred Baumgarth

Christian Sirrenberg

Hartmut Greiner

David Bruge

Wolfgang Staehle

Lars Thore Burgdorf

Ulrich Graedler

Bertram Cezanne

Simon Lawrence Goodman

Marcus Eber

Djordje Musil

Per Hillertz

Nina Heiss

The present invention relates to a pharmaceutical composition of oligopeptides, preferably cyclic oligopeptides, said composition further comprising one or more lipophilic and/or amphiphilic compounds, in the presence or absence of water as the main ingredients, the use of the lipophilic and/or amphiphilic compounds for making pharmaceutical compositions of said oligopeptides, and methods of making said pharmaceutical composition.

Method of treating disorders using a pharmaceutical composition of oligopeptides

The compound 4-(2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-2,7-naphthyridin-1-ylamine and pharmaceutically usable salts and/or tautomers thereof. The use of this compound for the treatment of tumors, tumor growth, tumor metastases and/or AIDS.

7-azaindole-2,7-naphthyridine derivative for the treatment of tumours

The present invention relates to novel bipyridyl derivatives of formula (I) and to the use of such compounds in which the inhibition, regulation and/or modulation of signal transduction by ATP consuming proteins like kinases plays a role, particularly to inhibitors of TGF-beta receptor kinases, and to the use of such compounds for the treatment of kinase-induced diseases, in particular for the treatment of tumors.

Bipyridyl derivatives

The present invention relates to novel pyrido[2,3-b]pyrazine compounds of formula (I): and to the use of such compounds in which the inhibition, regulation and/or modulation of signal transduction by ATP consuming proteins like kinases plays a role, particularly to inhibitors of TGF-beta receptor kinases, and to the use of such compounds for the treatment of kinase-induced diseases, in particular for the treatment of tumors.

Pyrido [2, 3-B] pyrazine compounds and their therapeutical uses such as for inhibiting ATP consuming proteins and treating diseases associated therewith

Novel hetarylaminoquinoline derivatives of formula (I) wherein X, Z, Het, R1, R2, R3 and R4 have the meaning according to claim, are inhibitors of ATP consuming proteins, and can be employed, inter alia, for the treatment of tumors.

Heteroarylaminoquinolines as TGF-beta receptor kinase inhibitors

Novel hetaryl-[1,8]naphthyridine derivatives of formula (I) wherein R1, R2, W, W, Wand Whave the meaning according to claim, are inhibitors of ATP consuming proteins, and can be employed, inter alia, for the treatment of tumors.

Hetaryl-[1,8]naphthyridine derivatives

Novel hetarylaminonaphthyridine derivatives of formula (I) wherein X, R1, R2, R3, R4, W1, W2, W3, W5 and W6 have the meaning according to claim, are inhibitors of ATP consuming proteins, and can be employed, inter alia, for the treatment of tumors.

Hetarylaminonaphthyridines

The present invention relates to novel [1,8]naphthyridine derivatives of formula (I) and to the use of such compounds in which the inhibition, regulation and/or modulation of signal transduction by ATP consuming proteins like kinases plays a role, particularly to inhibitors of TGF-beta receptor kinases, and to the use of such compounds for the treatment of kinase-induced diseases, in particular for the treatment of tumors.

2,4-diaryl-substituted [1,8] naphthyridines as kinase inhibitors for use against cancer

Compounds of the formula (I), in which R, R, R, R, R, X, Y, W, Q, Q, Z, s and m have the meanings indicated in Claim, can be employed, inter alia, for the treatment of tumors.

Substituted tetrahydroquinolines

The present invention relates to methylene urea derivatives of formula (I), the use of the compounds of formula (I) as inhibitors of raf-kinase, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.

Methylene urea derivatives

Compounds of the formula (I), in which W, R, R, R, R, R, R, Rand Rhave the meanings indicated in Claim, can be employed, inter alia, for the treatment of tumors. 

Tetrahydroquinolines for use as modulators of the mitotic motor protein Eg5

Novel 5-cyanothienopyridines of the formula (I), in which R, Rand Rhave the meanings indicated in claim, are inhibitors of TGF-beta receptor kinase, and can be employed, inter alia, for the treatment of tumors.

5-cyanothienopyridines for the treatment of tumours

Compounds of the formula I, in which s, k, I, W, R, R, R, and U have the meanings indicated in claim, can be employed, inter alia, for the treatment of tumours. 

Growing community of inventors

Muehltal/Trautheim, Germany

Christiane Amendt